Podcasts about acr convergence

Uncover the power of advocacy and community in rheumatology as we welcome our empowering guests, Jennifer Weaver and Cheryl Crow. Jennifer, a dedicated patient leader, and Cheryl, an occupational therapist and founder of Arthritis Life, open up about their journeys as Rheum Champions at the ACR Convergence 2024. With a promise of insight and inspiration, we navigate the intricacies of large conferences, including the importance of patient voices at the table and the small yet significant moments that define their experiences.Balancing the realities of healthcare challenges with triumphs, our conversation shifts to the heart of patient advocacy. Dive into the emotional, and at times, hopeful connections formed between patient advocates and medical professionals. Cheryl and Jennifer share personal stories on navigating sleep hygiene, the subtle pressures of defining "normal," and the importance of sensitivity in language. Through these reflections, we emphasize a broader understanding and embrace of diverse health experiences.Explore the intricate world of rheumatology and the complexities of comorbidities like POTS, long COVID, and rheumatoid arthritis. We also shine a light on recent advancements in lupus treatment and managing chronic pain with "positive activity scheduling." Our discussion concludes with an homage to the supportive sisterhood that empowers us, urging listeners to connect with organizations like the Dysautonomia Association and Creaky Joints. As we wrap up, we celebrate the strength found in shared experiences and encourage you to stay engaged for future episodes.Jen: Rheum Champions - The Rheumatology Lab https://www.instagram.com/gracefully_jen/?__pwa=1Welcome to Gracefully Jen | Instagram, Facebook, TikTok | LinktreeCheryl: Rheum Champions - The Rheumatology Labhttps://www.instagram.com/arthritis_life_cheryl/https://thoughtful-experimenter-636.ck.page/1fb879479cSend us a text Are you living with a chronic illness and want to make your voice heard? Rare Patient Voice connects patients and caregivers with research opportunities—so you can share your experiences and get paid for your time! Your insights help drive real change in healthcare.Let's Get Started - Rare Patient Voice Support the showSupport:https://rarepatientvoice.com/Myspooniesisters/https://www.etsy.com/shop/MySpoonieSistershttps://www.graceandable.com/?bg_ref=980:nzTyG6c9zK (Use code GAJen10)Website:https://myspooniesisters.com/ Discount Codes: GIANT Microbes | Gag Gifts, Teacher Gifts, Doctor Gifts, Gifts for Girlfriends and Boyfriends code SPOONIE20 for 20% off

On this episode of Biotech Hangout, Eric Schmidt, Bruce Booth, Yaron Werber, Tim Opler and Mike Yee begin the show discussing the highlights from the Jefferies Healthcare Conference before taking a look at public investor sentiment this week. The discussion turns to Atlas Venture's 2024 Year in Review and transitions into the emerging themes for 2025. The hosts also recap ACR Convergence including Amgen's Phase 3 data as well as data from cell therapies for SLE, SSC, IMNM. The group also discuss lipid readouts from Eli Lilly, Silence Therapeutics and NewAmsterdam Pharma. Other topics covered include the Incyte and Escient deal collapse, Kura Oncology's pact with Kyowa Kirin, and perspectives on Trump's nomination of Dr. Mehmet Oz to lead the CMS. This episode aired on November 22, 2024.

In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Children's HospitalAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Join Olivier and Pierre and hear from 3 winners of the EMEUNET Top 10 Abstracts! Listen to Jacob Koopman, Johannes Knitza and Andreas Kerschbaumer to find out more about their work and their experience of the ACR Convergence!

As 2024 ends, the ACR's Government Affairs Committee looks ahead to the 119th Congress to address key issues in rheumatology. For our second annual legislative and policy update, we're joined by Dr. Lennie McDaniel, head of ACR's Washington DC office, and Dr. Christina Downey, Chair of the Government Affairs Committee, to share insights from their ACR Convergence 2024 session. Topics include Medicare cuts, physician payments, pharmacy benefit managers (PBMs), telemedicine reimbursement changes, and how you can advocate for better outcomes with the ACR. 

Yvonne C. Lee, MD, shares key takeaways from her ACR Convergence presentation on sleep disturbances in patients with rheumatoid diseases. Additionally, Dr. Lee gives an overview of the meeting's standout presentations.

Yvonne C. Lee, MD, shares key takeaways from her ACR Convergence presentation on sleep disturbances in patients with rheumatoid diseases. Additionally, Dr. Lee gives an overview of the meeting's standout presentations.

In this episode our host Dr Raquel Faria covers key highlights from the ACR Convergence 2024, including groundbreaking research on SLE and lupus nephritis management, new clinical trial strategies, mechanisms of disease and patient reported outcomes. Tune in for insights from Prof David Isenberg on pivotal studies and expert discussions that shape the future of lupus care. Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company's Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo. Additionally, the treatment demonstrated comprehensive benefits, achieving statistical significance across six key secondary measures: improved sleep quality, reduced fatigue, enhanced physical function, better overall symptoms, and increased patient satisfaction. The medication, which was generally well-tolerated with no new safety concerns, represents a potential breakthrough for fibromyalgia patients. Tonix submitted a New Drug Application (NDA) to the FDA in October 2024, with an anticipated decision in 2025. If approved, this would mark the first new fibromyalgia treatment in over 15 years, offering a novel approach by addressing sleep disturbances. Dr. Lederman also highlighted other recent milestones, including Fast Track designation from the FDA and a $34 million Department of Defense contract for antiviral research. With $28 million in cash reserves reported at the close of Q3, Tonix Pharmaceuticals is well-positioned for continued innovation and growth. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #FibromyalgiaTreatment #FDAApproval #PharmaNews #DrugDevelopment #SethLederman #PharmaceuticalInnovation #MedicalBreakthrough #FastTrackDesignation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don't miss our live coverage of key takeaways and trends shaping the future of patient care. Join us live and stay at the forefront of rheumatology!

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don't miss our live coverage of key takeaways and trends shaping the future of patient care. Join us live and stay at the forefront of rheumatology!

We're reporting live from the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C., a yearly gathering for rheumatology experts worldwide. Join us as we talk to rheumatologists, researchers, and patients to discover how these advancements in research are shaping the future of health and advocacy. Among the highlights in this episode: 00:43: Dr. Sharon Dowell discusses her background as a rheumatologist and her favorite ACR session, "Thieves Market," which emphasizes the diversity of rheumatology cases 01:27: Dr. Dowell explains how events like ACR enhance advocacy by providing opportunities for networking and sharing global perspectives on patient care 02:24: Dr. Swamy Venuturupalli shares his excitement about lupus-specific sessions, especially on CAR T cell therapy, and how these advancements could help his patients 03:36: Dr. Venuturupalli emphasizes the importance of ACR as a global platform for learning and collaboration in rheumatology research 04:25: Cristina Montoya, a registered dietitian and patient advocate, shares her experience presenting on unrecognized symptoms of rheumatic diseases 05:29: Cristina highlights her work with the OMERACT Children's Disease Working Group and her contributions to developing new outcomes for clinical trials 06:44: Dr. Shilpa Venkatachalam reflects on the patient-centered focus at ACR 2024 and the collaborative advancements in biologics and treatment modalities 09:02: Dr. Venkatachalam explains the value of patient-centered research in making invisible diseases visible through patient-reported outcomes and clinical data 12:06: Dr. Venkatachalam discusses how tools like PatientSpot empower patients to advocate for themselves by providing a full picture of their lived experiences For more information about PatientSpot, visit: https://patientspot.org/ 13:14: Zoe wraps up the episode, emphasizing the significance of research presented at ACR in improving patient outcomes and advocacy efforts Contact Our Hosts Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Director of Community Outreach at GHLF: zrothblatt@ghlf.org A podcast episode produced by Ben Blanc, Associate Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

We are proud to present the highly anticipated “ACR 2024 Lupus Nephritis Guideline” with First Author and frequent guest, Dr. Lisa R. Sammaritano. A decade in the making, we reflect on the significant advancements in available therapies, the guideline's holistic approach to managing Lupus Nephritis (LN) across all age groups, and include insights on combination therapies, minimizing glucocorticoid use and how to manage the full spectrum of patients with Lupus Nephritis. 

As our weekend here in Washington D.C. draws to an end, we turn our spotlight on an important and timely conversation from the "Sponsoring Women in Science" session. In this episode, we sit down with Dr. Elizabeth Volkmann and Dr. Carol Feghali-Bostwick to explore the challenges women face in advancing their careers in the sciences. Our guests share insights on how to address the barriers that often impede career development for women, discuss strategies for fostering support and mentorship, and highlight the importance of growing awareness around these critical issues.

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don't miss our live coverage of key takeaways and trends shaping the future of patient care. Join us live and stay at the forefront of rheumatology!

As we continue to highlight sessions from Convergence 2024, we came upon this talk we think you should not miss: Emerging Threats in Rheumatology: Chronic Chikungunya Arthritis and Syphilis Mimicking Rheumatic Diseases. Session presenters, Dr. Jose Kennedy Amaral Pereira and Dr. Daniela DiMarco help us explore the world of emerging threats in rheumatology: specifically, Chikungunya Arthritis and Syphilis. These two experts share insights with us to help diagnose and manage those with these devastating infections and highlight for us how important it is for rheumatologists to remain on high alert for these infections, which can be easily mistaken for more common rheumatic disorders! 

Get ready for an electrifying episode of Convergence 2024! We're diving deep into the cutting-edge world of autoinflammatory diseases with renowned experts Drs. Grant Schulert and Arthur Kaser. Join us as they unravel the complexities of refractory and complicated systemic juvenile idiopathic arthritis (SJIA). Discover the revolutionary insights into SJIA at the single-cell level, explore the fascinating transcriptional diversity of normal and low-density granulocytes, and learn how groundbreaking approaches like UDON and SATAY-UDON are paving the way for novel disease programs. Don't miss this chance to fuel your passion for innovation in medicine—tune in and ignite your curiosity! 

Can Artificial Intelligence (AI) ever replace the clinician or the researcher? Today, we explore the promises and pitfalls of this transformative technology and its implications for rheumatology. From assistance in diagnosis and patient care to its role in research and academic writing, our two guests Dr. Amanda Nelson and Dr. Bella Mehta will walk us through how our field is utilizing AI today and where it may lead in the near future. Most of all, they'll explain how we can harness its power...without getting burned. 

Este 17, 18, 19 y 20 de noviembre de 2024 estaremos publicando los resúmenes de cubrimiento del congreso del colegio americano de reumatología (ACR Convergence) 2024.Te invitamos a que visites www.reumatimes.com, te inscribas gratis y revises el contenido que día a día estarán revisando nuestros expertos para que de una forma práctica y concisa estés al día en la reumatología.Te invitamos a que participes en la sección de comentarios. ¿Qué quieres escuchar? ¿Cuáles son tus temas de interés?Síguenos en www.reumatimes.com, donde podrás encontrar cubrimientos de congresos de reumatología y resúmenes de actualidad en la especialidad.Encuéntranos en YouTube como ReumaTimes Y Facebook como Reumatologia.Online o ReumaTimes, en Instagram como dr.sebastianherrera o ReumaTimes, y en X (antes Twitter) como @Reuma_Online_ o @ReumaTimes. Estamos también en TikTok como @Reuma_Times.Síguenos en www.reumatimes.comTambién puedes encontrarnos en:Twitter: https://twitter.com/Reuma_Online_Facebook: https://www.facebook.com/reumatologiaonline/Instagram: https://www.instagram.com/dr.sebastianherrera/Spreaker: https://www.spreaker.com/user/11390404Spotify: https://spoti.fi/3DILwLP

Our annual preview episode for Convergence is here, and we have AMPC (Annual Meeting Planning Committee) Chair, Dr. Greg Gardner as our guest! Dr. Gardner walks us through this meeting's focus and strategies, which are designed to make ACR24 even more engaging, delivering cutting edge science, more networking opportunities, improved educational experiences and new initiatives to better the lives of our patients. We'll discuss how Convergence has adapted to a post-pandemic era, get a glimpse of “must attend” sessions, and even hear about the new networking lounge and some insider tips to make the most of your stay in Washington D.C. 

In this episode of Meeting Mic, we bring you Healio's top headlines from ACR Convergence 2023.  Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19  Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09  Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating “many symptoms” of long COVID prior to initial infection. 12:00  Leonard H. Calabrese, DO, highlights the “year in review”, issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18   Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15  Read the full coverage here:  https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake  https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk   https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection   @LCalabreseDO  https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block  Disclosures:  Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences. 

In this weeks podcast, Dr. Jack Cush reviews the ACR Convergence 2023 meeting and proposes how to best learn at large medical meetings:

Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at the 2023 ACR Convergence meeting in San Diego, CA.

Dr. Jack Cush reviews this past weeks news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.

Welcome to "ACR Convergence on Air" (ACoA)! Our daily coverage of ACR Convergence 2023! First up: what is thrombotic microangiopathy (TMA) and what is its significance for rheumatology? How does TMA present in clinic and what are the challenges in diagnosing it? Chief of the Division of Hematology and Medical Director of the Clinical Coagulation and the Platelet Antibody Laboratories at Duke University, Dr. Thomas Ortel, joins us on the show to explain this and more from his presentation here at Convergence 2023 

ACR Convergence 2023 begins this Saturday! Dr. Hausmann gets on the mic for this short preview to unveil all of the exciting new things you'll hear, all week long, on our podcast! Be sure to wake up with Jon this Saturday morning, and every morning, during this year's Convergence!

ACR Convergence 2023 is very nearly here, and with it only being a few weeks away, it's also time for our annual preview episode! What's new this year? What returning favorites are coming back? What can we expect from the San Diego Convention Center? Jon talks to our AMPC Chair, Dr. Sharon Kolasinski once more to tease this year's meeting, which in many ways builds on your feedback from last year as well. While listening, why not explore our Full Schedule or even Register Today! Enjoy the show and we'll see you in November! 

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00 Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00 Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan's effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00 Read the full coverage here: Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer Elacestrant extends PFS among certain women with metastatic breast cancer Trastuzumab deruxtecan ‘new gold standard' in second line for breast cancer subset Ribociclib regimen may be superior to chemotherapy in advanced breast cancer Breast cancer specialist receives lecture award Genomic assay may predict ovarian function suppression benefit in breast cancer subset Disclosures: Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi. Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant. Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers' relevant financial disclosures.

This week, Dr. Alfred Kim joins Dr. Hausmann for a reflective episode, highlighting memorable moments and key learning takeaways from ACR Convergence 2022, in our final episode of the year. Have a happy and healthy new year.   

Leading experts in rheumatology from all over the world convened at the American College of Rheumatology annual scientific meeting, ACR Convergence. In this episode, Rebecca talks to some of the rheumatologists and scientists about their work and presentations, and to other patients who participated. Hear about some of the research, treatments and trends that have emerged in the past year. *Visit the Live Yes! With Arthritis Podcast episode page get show notes and read the full transcript: https://www.arthritis.org/liveyes/podcast/new-podcast/ep69-2022-arthritis-research-highlights * We want to hear from you. Tell us what you think about the Live Yes! With Arthritis Podcast. Get started by emailing podcast@arthritis.org. Special Guests: Cheryl Crow, MOT, OTR/L, Daniel H. Solomon, MD, MPH, David T. Felson, MD, MPH, Jean Liew, MD, MS, and Megan E.B. Clowse, MD, MPH.

With most Americans recently celebrating Thanksgiving by joining friends and family over a large, turkey-heavy celebratory meal, we take an inDEPTH look at how our bodies deal with excess nitrogen. Animals mostly excrete excess nitrogen as ammonia, urea, or uric acid, which is produced during protein metabolism. Ammonia is the direct waste produced as a byproduct of protein metabolism by all animals. But because of its toxicity, many animals convert ammonia into a less toxic form. The major excretory product in humans is urea, which is excreted in urine by the kidneys. Fun fact: birds and reptiles have evolved the ability to convert toxic ammonia into uric acid, which packs four nitrogens into each molecule, compared with two nitrogens in each human urea molecule. Not only is that a much more efficient means of excreting nitrogen, uric acid is a white crystal precipitate, which is why guano is white and makes such an excellent fertilizer.Humans have many diseases caused by excess nitrogen. Later in this episode, we will talk with Dr. Julien Baruteau, from the Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, in London, UK, about how his lab goes about modeling urea cycle disorders using patient cells. But first, we speak with Dr. Michael Pillinger (NYU Grossman School of Medicine, NY), about how gout flares result from an innate immune response against monosodium urate crystal deposits, and about his recent results from the PIVOTAL study, presented at the ACR Convergence 2022 meeting.  

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Alfred Kim, MD, discusses some key take-home points from the Long COVID presentation :18 Giovanni Adami, MD, reviews the impact of tofacitinib on fracture risk in patients with rheumatoid arthritis and the effect of glucocorticoids on bone density. 3:39 Leonard Calabrese, DO, gives a long-view of the meeting and the sessions he attended. 6:06   Paul Emery, MD, discusses results of a phase 2 study of peresolimab for adults with rheumatoid arthritis. 9:32 Read the full coverage here: https://www.healio.com/news/rheumatology/ 20221112/understanding- of-long-covid-shifting-at- breakneck-speed  https://www.healio.com/news/rheumatology/ 20221122/bonesafe-glucocorticoid- dose-hard-to-find-in- rheumatic-musculoskeletal- diseases https://www.healio.com/news/rheumatology/ 20221121/pd1-agonist-generates-a-bit-of-excitement- in- rheumatoid- arthritis ACR: Varicella vaccine strongly recommended in all immunosuppressed adults ‘Anatomy inventory' fosters more inclusive care for transgender, non-binary patients 'Strange times': Prescribing methotrexate legally ‘low risk' Post-Roe Disclosures: Adami reports consultant roles with Amgen, BMS, Eli Lilly, Fresenius Kabi, Galapagos, Theramex and UCB. Calabrese reports consultant roles with AstraZeneca and GSK. Emery reports relationships with AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, Novartis, Pfizer, Roche and Samsung. Kim reports no relevant financial disclosures.

The Health Advocates share several takeaways from attending the 2022 American College of Rheumatology Convergence (ACR), a meeting where rheumatology health professionals from around the world gather to share best clinical practices and cutting edge-research. A highlight of the conference was the patient perspective posters, and our hosts got to speak with a few of the patient presenters about their experiences. Stephanie Aleite, a Mental/Behavioral Health Fellow and patient advocate, created “Engaging with the Spoon Theory” to help her patient peers prioritize how they expend energy. “My hope is that by using this, patients feel empowered to make more meaningful decisions about engaging with their support system and really prioritize events that can give the biggest emotional payoff.” Among the highlights in this episode: 1:17: Listener comment 2:12: What is the American College of Rheumatology (ACR) Convergence and why does it matter? 2:35: The impact of ACR on the patient community 3:16: There is currently a shortage of rheumatologists in many countries and regions around the world 3:50: “There was a lot of talk about the need to humanize health care, to make medication more accessible, and the idea of working together to find better solutions,” says Steven Newmark, Director of Policy at GHLF 4:55: Another takeaway from the conference is the reminder that patients and health care workers are still facing COVID-19 5:43: “Patients are invited to submit a poster about an intervention that helped them improve their health… These patient perspectives are a really important part of a conference that's geared towards doctors… There's really no one-size-fits-all approach when it comes to medicine, and getting that patient voice and patient perspective helps doctors personalize their care,” says Zoe Rothblatt, Associate Director of Community Outreach at GHLF 8:09: Stephanie Aleite presents her poster: Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis that Works to Improve My Mental Health While Living With RA 8:16: “The intervention that I created… is a cost benefit analysis… to help patients increase the connection they have with their support system,” says Stephanie 13:09: Ashley Krivohlavek presents her poster: Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis 16:03: “The ACR is so amazing, because it puts our writers and people that are working in the rheumatology community in the same building as patients,” says Ashley 18:26: Eileen Davidson presents her poster: From Devastated to Empowered: How Patient Engagement in Research Changes Lives 19:26: “I think it's really important for clinicians to understand that patients can get involved like this because often medical appointments are infrequent, there are long waitlists, you won't necessarily find the answers that you need to, but this is an avenue [ACR] where you can get information and resources for living with your condition outside of the doctor's office,” says Eileen 20:41: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Welcome to ACR Convergence 2022! Today, Dr. Vicki Shanmugam (host of ACR Journals on Air) joins Jon to tackle three, pivotal trials, that will be presented at our annual meeting this year! Join us as they dive into the objectives, the science behind them and their incredible results. You can find each one of the manuscripts discussed on this episode here: Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo-Controlled Trial  

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.

ACR Convergence 2022 is almost here, and with that, new trials, new medications and new results. We're preparing a very HOT episode for you, to be released along with the opening ceremony at ACR Convergence 2022, this Saturday, November 12th. In this preview of Saturday's full episode, we've invited host of “ACR Journals on Air” Dr. Vicki Shanmugam, to briefly discuss all the exciting science that is just a few days away! 

Excited for ACR Convergence 2022? So are we! This week Jon catches up with AMPC Chair, Dr. Sharon Kolasinski! It's been two years since we've gathered physically, and when we meet up at The Philadelphia Convention Center, you won't be disappointed. Dr. Kolasinski dives into this year's program, new features at Convergence and even the delicious dining to be had in this historic city of brotherly love. See you soon! 

During “The Great Debate” at ACR Convergence 2020, the question: “Should JAK inhibitors be started before TNF inhibitors in people with rheumatoid arthritis who failed methotrexate?” was asked. However, in 2021, results from the oral surveillance trial showed an increased risk of major adverse cardiovascular events in cancers among patients with rheumatoid arthritis taking tofacitinib as compared to those on TNF inhibitors. These findings led to the FDA updating their black box warning on JAK inhibitors. Today, we've invited one of the speakers on the great debate, Dr. Vibeke Strand, to speak on her position on JAK inhibitors given these new results and shed some more light on the subject. 

Eric Ruderman MD shares the research presented at ACR Convergence 2021 in November that looked at rheumatic disease activity following COVID-19 vaccination. He explores whether immunosuppressive medications affect vaccine effectiveness and any contraindications to COVID-19 vaccination for patients with rheumatic disease. Lastly, he discusses the timing or use considerations for immunomodulatory therapy in relation to COVID-19 vaccination and other important considerations for providers caring for patients with rheumatic disease in the COVID-19 era.

In this second of two podcasts, hear Dr Robin Dore discuss key information from ACR Convergence 2021, including the use of COVID-19 vaccine in immunosuppressed adults with autoimmune diseases; the cardiovascular risk of hydroxychloroquine in rheumatoid arthritis; whether the boxed warning for romosozumab helps prevent inappropriate use in postmenopausal women with osteoporosis and a history of myocardial infarction or stroke; how the incidence of cardiovascular events in patients with rheumatoid arthritis compares with that of patients with diabetes; and evaluating the risk of mortality in patients with suboptimally treated gout. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.

In this first of two podcasts, hear Dr Vibeke Strand discuss key information from ACR Convergence 2021, including the potential to intervene in patients who are at high risk for developing rheumatoid arthritis; whether vitamin D3 and n-3 fatty acids can prevent autoimmune disease; the Food and Drug Administration's perspective on the safety of Janus kinase inhibitors; and results from a phase 3b/4 randomized safety study of tofacitinib vs tumor necrosis factor inhibitors. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.

Health care disparities in rheumatology have been shown to have a significantly negative effect on quality of life and patient outcomes. There are several factors that drive health inequities in the US, including race, ethnicity, and socioeconomics, such as education, health care access, and income. In the first episode of the ACR Convergence 2021 series, we speak with rheumatologist Iris Y. Navarro-Millán, MD, who provides a deeper insight into understanding social determinants of health as drivers of health disparities in rheumatology and urges researchers and clinicians to look beyond just race and ethnicity when addressing these disparities.

Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, about the highlights of ACR Convergence 2021, which was held virtually on 3-9 November (https://www.rheumatology.org/Annual-Meeting).

Dr Cush reviews the news and kicks off ACR21 learning and how to take in the annual meeting

Dr Cush reviews the news and kicks off ACR21 learning and how to take in the annual meeting

A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.

If you are too busy to read the EMEUNET website, this podcast is exactly for you. Now you can get updated while on the go, with highlights of the most recent publications or interviews in the field of Rheumatology, selected for you by EMEUNET members. In this episode, Diego Benavent brings us the highlights from the American College of Rheumatology (ACR) Convergence 2020.

In this episode we welcome guests Dr. Akrithi Udupa and Dr. Allen Witt from Duke, and Dr. Guy Katz from MGH to discuss four topics from the 2020 ACR Convergence conference that could be teams in the upcoming RheumMadness tournament.  The topics we discuss are:1. Draft 2020 RA Guidelines2. Belimumab for Lupus Nephritis3. Pregnancy with ILD in Rheumatic Disease4. IL-16 as a Biomarker of Lupus NephritisRheumMadness Music Attribution: Cheery Monday by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3495-cheery-mondayLicense: http://creativecommons.org/licenses/by/4.0/